Lenvatinib

Brand names: Lenvima · Active ingredient: Lenvatinib

In short: LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line

Forms & strengthsCapsules: 4 mg: yellowish-red body and yellowish-red cap, marked in black ink with “Є” on cap and “LENV 4 mg” on body. 10 mg: yellow body and yellowish-red cap, marked in black ink with “Є” on cap and “LENV 10 mg” on body.
LabelEisai Inc.
Label updatedOct 22, 2026

What is Lenvatinib used for?

LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).

LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.

LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation

.

Lenvatinib dosage

For the pMMR/not MSI-H advanced endometrial carcinoma indication, select patients for treatment with LENVIMA in combination with pembrolizumab based on MMR or MSI status in tumor specimens .

Information on FDA-authorized tests for patient selection is available at: http://www.fda.gov/CompanionDiagnostics.

Reduce the dose for certain patients with renal or hepatic impairment .

Take LENVIMA once daily, with or without food, at the same time each day . If a dose is missed and cannot be taken within 12 hours, skip that dose and take the next dose at the usual time of administration.

Table 1: Recommended Dosage

Indication | Recommended Dosage of LENVIMA | Duration of Treatment

Monotherapy

DTC | 24 mg orally once daily | Until disease progression or unacceptable toxicity.

HCC | Patients with a body weight of greater than or equal to 60 kg: 12 mg orally once daily

Patients with a body weight of less than 60 kg: 8 mg orally once daily | Until disease progression or unacceptable toxicity.

Combination Therapy

a

First line treatment of advanced RCC | 20 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph | Until disease progression or unacceptable toxicity.After completing 2 years of combination therapy, LENVIMA may be administered as a single agent until disease progression or until unacceptable toxicity.

Advanced ccRCC | 20 mg orally once daily in combination with belzutifan | Until disease progression or unacceptable toxicity.

Advanced RCC | 18 mg orally once daily in combination with 5 mg everolimus orally once daily | Until disease progression or unacceptable toxicity.

EC | 20 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph | Until disease progression or unacceptable toxicity.

a Refer to the Prescribing Information for the agents administered in combination with LENVIMA for recommended dosing information.

Recommendations for LENVIMA dose interruption, reduction and discontinuation for adverse reactions are listed in Table 2. Table 3 lists the recommended dosage reductions of LENVIMA for adverse reactions.

Table

2

:

Recommended Dos

ag

e Modifications for LENVIMA for Adverse Reactions

Adverse Reaction | Severity

a | Dos

ag

e Modifications for LENVIMA

Hypertension | Grade 3 | Withhold for Grade 3 that persists despite optimal antihypertensive therapy.

Resume at reduced dose when hypertension is controlled at less than or equal to Grade 2.

Grade 4 | Permanently discontinue.

Cardiac Dysfunction | Grade 3 | Withhold until LVEF improves to baseline or Grade 1.

Resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.

Grade 4 | Permanently discontinue. …

How to take Lenvatinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypertension

Advise patients to undergo regular blood pressure monitoring and to contact their healthcare provider if blood pressure is elevated

.

Cardiac Dysfunction

Advise patients that LENVIMA can cause cardiac dysfunction and to immediately contact their healthcare provider if they experience any symptoms or signs of cardiac dysfunction .

Arterial Thrombotic Events

Advise patients to seek immediate medical attention for new onset chest pain or acute neurologic symptoms consistent with myocardial infarction or stroke .

Hepatotoxicity

Advise patients that they will need to undergo laboratory tests to monitor liver function and to report any new symptoms indicating hepatic toxicity or failure .

Proteinuria and Renal Failure/Impairment

Advise patients that they will need to undergo regular laboratory tests to monitor kidney function and protein in the urine .

Diarrhea

Advise patients when to start standard anti-diarrheal therapy and to maintain adequate hydration. Advise patients to contact their healthcare provider if they are unable to maintain adequate hydration . …

Warnings & precautions

Do not take this medicine if: None.

Hypertension occurred in 73% of patients in SELECT (DTC) receiving LENVIMA 24 mg orally once daily and in 45% of patients in REFLECT (HCC) receiving LENVIMA 8 mg or 12 mg orally once daily. The median time to onset of new or worsening hypertension was 16 days in SELECT and 26 days in REFLECT. Grade 3 hypertension occurred in 44% of patients in SELECT and in 24% in REFLECT. Grade 4 hypertension occurred <1% in SELECT and Grade 4 hypertension was not reported in REFLECT.

In patients receiving LENVIMA 18 mg orally once daily with everolimus in Study 205 (RCC), hypertension was reported in 42% of patients and the median time to onset of new or worsening hypertension was 35 days. Grade 3 hypertension occurred in 13% of patients. Systolic blood pressure ≥160 mmHg occurred in 29% of patients and diastolic blood pressure ≥100 mmHg occurred in 21% .

Serious complications of poorly controlled hypertension have been reported.

Control blood pressure prior to initiating LENVIMA. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at a reduced dose when hypertension is controlled or permanently discontinue LENVIMA based on severity .

Serious and fatal cardiac dysfunction, including heart failure with reduced left ventricular ejection fraction (LVEF), and cardiomyopathy, can occur with LENVIMA. The safety of LENVIMA either as monotherapy or in combination with belzutifan has not been established in patients with LVEF below 50%.

Across clinical trials in 799 patients with DTC, RCC or HCC, Grade 3 or higher cardiac dysfunction adverse events occurred in 1% of LENVIMA-treated patients. The median time to onset of Grade 3 or higher cardiac dysfunction was 35 weeks (range 7 to 63 weeks). …

Lenvatinib side effects

The following adverse reactions are discussed elsewhere in the labeling:

Hypertension

Cardiac Dysfunction

Arterial Thromboembolic Events

Hepatotoxicity

Renal Failure and Impairment

Proteinuria

Diarrhea

Fistula Formation and Gastrointestinal Perforation

QTc Interval Prolongation

Hypocalcemia

Reversible Posterior Leukoencephalopathy Syndrome

Hemorrhagic Events

Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction

Impaired Wound Healing

Osteonecrosis of the Jaw (ONJ)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in the Warnings and Precautions reflect exposure to LENVIMA as a single agent in 261 patients with DTC (SELECT) and 476 patients with HCC (REFLECT), LENVIMA with pembrolizumab in 406 patients with EC (Study 309), LENVIMA with everolimus in 62 patients with RCC (Study 205), LENVIMA with pembrolizumab in 352 patients with RCC (CLEAR), and LENVIMA with belzutifan in 370 patients with RCC (LITESPARK-011). Safety data obtained in 1823 patients with advanced solid tumors who received LENVIMA as a single agent across multiple clinical studies was used to further characterize the risks of serious adverse reactions. …

Drug interactions

LENVIMA has been reported to prolong the QT/QTc interval. Avoid coadministration of LENVIMA with medicinal products with a known potential to prolong the QT/QTc interval .

About this medicine

LENVIMA, a kinase inhibitor, is the mesylate salt of lenvatinib. Its chemical name is 4-[3-chloro-4-(N’-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate. The molecular formula is C21H19ClN4O4 • CH4O3S, and the molecular weight of the mesylate salt is 522.96. The chemical structure of lenvatinib mesylate is:

Lenvatinib mesylate is a white to pale reddish yellow powder. It is slightly soluble in water and practically insoluble in ethanol (dehydrated). The dissociation constant (pKa value) of lenvatinib mesylate is 5.05 at 25°C. The partition coefficient (log P value) is 3.3.

LENVIMA capsules for oral administration contain 4 mg or 10 mg of lenvatinib, equivalent to 4.90 mg or 12.25 mg of lenvatinib mesylate, respectively. The inactive ingredients are: calcium carbonate, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and talc.

In addition, the capsule shell contains ferric oxide red, ferric oxide yellow, hypromellose, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f4bedd21-efde-44c6-9d9c-b48b78d7ed1e. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone